SAB Biotherapeutics Warrant
SABSW
10 hedge funds and large institutions have $38.1K invested in SAB Biotherapeutics Warrant in 2023 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 0 closing their positions.
11% more funds holding
Funds holding: 9 → 10 (+1)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
0.11% less ownership
Funds ownership: 2.51% → 2.41% (-0.11%)
59% less capital invested
Capital invested by funds: $93K → $38.1K (-$55K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$1.75K |
| 2 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
+$605 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Shaolin Capital Management
Miami,
Florida
|
-$5.66K |
SABSW Hedge Fund Activity: Q4 2023 in Review
10 of the 6,871 institutional investors tracked by Wall St. Rank reported a position in SAB Biotherapeutics Warrant (SABSW) for Q4 2023, worth a combined $38.1K — down 59% from $93K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new SABSW positions and 0 closed out — a net gain of 1 holder — while 1 added to existing stakes and 1 trimmed.
The largest buyer was UBS Group, opening a new position worth an estimated $1.75K. The largest seller was Shaolin Capital Management, cutting an estimated $5.66K.
- 10 institutional investors held SAB Biotherapeutics Warrant (SABSW) as of Q4 2023, up from 9 in Q3 2023.
- Funds reported $38.1K of SAB Biotherapeutics Warrant stock for Q4 2023, down 59% quarter-over-quarter.
- 1 fund opened new SAB Biotherapeutics Warrant positions in Q4 2023 and 0 closed out, a net change of +1 holder.
- The largest SAB Biotherapeutics Warrant buyer in Q4 2023 was UBS Group, an estimated $1.75K added.
- The largest SAB Biotherapeutics Warrant seller in Q4 2023 was Shaolin Capital Management, an estimated $5.66K sold.
Based on aggregated 13F filings for Q4 2023.